Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison.

Beyer, Jörg; Schwella, N.; Zingsem, J.; Strohscheer, Imke; Schwaner, Ingo; Oettle, Helmut; Serke, Stefan; Huhn, D.; Stieger, W

doi:10.1200/jco.1995.13.6.1328

Cited by 260 publications

(143 citation statements)

References 30 publications

Supporting

Mentioning

132

Contrasting

Unclassified

Order By: Relevance

“…34,56,57 The target dose of infused CD34 þ cells varies from a minimum of 2.0 Â 10 6 CD34 þ cells/kg 31,58,59 to an optimal level of 5.0 Â 10 6 CD34 þ cells/kg. 24,26,55 Within this range, higher doses of infused CD34 þ cells are more beneficial for patients with MM and NHL.…”

Section: Mobilization Agent Mechanismmentioning

confidence: 99%

Improving stem cell mobilization strategies: future directions

Bensinger

DiPersio

McCarty

2009

Bone Marrow Transplant

203

209

View full text Add to dashboard Cite

Section: Mobilization Agent Mechanismmentioning

confidence: 99%

Improving stem cell mobilization strategies: future directions

Bensinger

DiPersio

McCarty

2009

Bone Marrow Transplant

203

209

View full text Add to dashboard Cite

“…Seven patients recovered hematopoiesis timely in a median of 12 days for ANC Ͼ0.5 ϫ 10 3 / l and 14 days for platelets Ͼ20 ϫ 10 3 / l, time-periods which have been reported in patients with solid tumors and hematologic diseases following HDCT and PBPC rescue. 15,16 One patient, however, exhibited delayed ANC recovery on day +37 and failed to recover platelets until hospital discharge on day +55. The day of platelet recovery could not be determined exactly, because the patient reached platelet numbers Ͼ20 ϫ 10 3 / l after hospital release.…”

Section: Discussionmentioning

confidence: 99%

“…In a randomized study it has been shown that patients with germ cell cancer, who underwent HDCT with subsequent PBPC reinfusion, recovered hematopoiesis significantly faster than patients rescued by bone marrow. 15 Therefore, the present study focused on the feasibility of mobilization and collection of PBPC in pretreated patients with metastatic STS. Mobilization of PBPC is usually performed by cyclophosphamide and/or growth factor in various malignant diseases.…”

Section: Discussionmentioning

confidence: 99%

“…They treated three groups of patients with escalating doses of EDR, 100 mg/m 2 , 120 mg/m 2 and 140 mg/m 2 , respectively, plus fixed-dose ifosfamide. Circulating CFU-GM showed peak values on median day 14 (12)(13)(14)(15)(16)(17) from beginning of chemotherapy. Maximal numbers of CFU-GM/ml occurred in the group with EDR 140 mg/m 2 and were approximately 42-fold higher than the baseline values.…”

Section: Discussionmentioning

confidence: 99%

“…12,13 More recently, the use of hematopoietic stem/progenitor cells has circumvented myelotoxicity as the dose-limiting toxicity in clinical trials. 14,15 The aim of this study was to demonstrate peripheral blood progenitor cell (PBPC) mobilization by diseasespecific chemotherapy in pretreated patients with metastatic STS scheduled for high-dose chemotherapy (HDCT). …”

mentioning

confidence: 99%

See 2 more Smart Citations

Mobilization of peripheral blood progenitor cells by disease-specific chemotherapy in patients with soft tissue sarcoma

Schwella

Rick

Meyer

et al. 1998

Bone Marrow Transplant

Self Cite

View full text Add to dashboard Cite

Summary:We investigated peripheral blood progenitor cell (PBPC) mobilization by disease-specific chemotherapy in patients with metastatic soft tissue sarcoma (STS). Nine patients, five females and four males, aged 12-51 years, pretreated by one to nine courses of cytotoxic chemotherapy, underwent STS-specific mobilization followed by G-CSF at 5 g/kg/day. PBPC were collected by 19 conventional-volume aphereses (8-12 l) with one to four procedures in individual patients. Leukaphereses started on median day 15 (range 13-18) from the first day of mobilization chemotherapy at medians of 25.8 ؋ 10 3 WBC/ l (6.8-46.9), 3.5 ؋ 10 3 MNC/ l (1.1-8.8), 122 ؋ 10 3 platelets/ l (72-293) and 30.7 CD34 ؉ cells/ l (6.7-207.8). Cumulative harvests resulted in medians of 4.6 ؋ 10 8 MNC/kg (3.0-6.4), 2.9 ؋ 10 6 CD34 ؉ cells/kg (1.1-11.1) and 12.0 ؋ 10 4 CFU-GM/kg (2.0-37.8). Eight patients underwent high-dose chemotherapy (HDCT) followed by PBPC rescue. Seven patients recovered hematopoiesis at medians of 12 days (8-15) for ANC Ͼ0.5 ؋ 10 3 / l and 14 days (8-27) for platelets Ͼ20 ؋ 10 3 / l. One patient, who received 1.6 ؋ 10 6 CD34 ؉ cells/kg, exhibited delayed ANC recovery on day ؉37 and failed to recover platelets until hospital discharge on day +55. We conclude that in patients with metastatic STS, who are pretreated by standard chemotherapy, PBPC can be mobilized by a further course of STS-specific chemotherapy plus G-CSF. One to four conventional-volume aphereses result in PBPC autografts that can serve as hematopoietic rescue for patients scheduled for HDCT. Keywords: soft tissue sarcoma; blood progenitor cells; disease-specific mobilization Soft tissue sarcomas (STS), arising from the extraskeletal connective tissue of the body, occur at a rate of 0.7% of all adult cancers. 1 Radical surgery, often combined with radiotherapy, can be curative in up to 60% of patients. However, prognosis of patients with metastatic or recurrent STS is poor, and most of them will die from progressive Treatment of patients who do not respond to these drugs is very difficult because only few salvage regimens exist. 6,7 There is strong evidence for a dose-response relationship for doxorubicin and ifosfamide. 8,9 For optimal response rates it seems essential to achieve a dose intensity of greater than 65 mg/m 2 for doxorubicin and greater than 5 g/m 2 for ifosfamide. 10,11 In the last decade, hematopoietic growth factors such as granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) have entered clinical trials in an attempt to administer escalated-dose chemotherapy regimens without inducing fatal neutropenia. 12,13 More recently, the use of hematopoietic stem/progenitor cells has circumvented myelotoxicity as the dose-limiting toxicity in clinical trials. 14,15 The aim of this study was to demonstrate peripheral blood progenitor cell (PBPC) mobilization by diseasespecific chemotherapy in pretreated patients with metastatic STS scheduled for high-dose chemotherapy (HDCT). Patients and methods Pa...

show abstract

Medical Treatment of Advanced Testicular Cancer

Feldman

Bosl²,

Sheinfeld³

et al. 2008

JAMA

335

225

View full text Add to dashboard Cite

ESTICULAR CANCER IS THE MOST common cancer diagnosis in men between the ages of 15 and 35 years, with approximately 8000 cases detected in the United States annually. 1 The majority (95%) of testicular neoplasms are germ cell tumors (GCTs), with other testicular neoplasms (ie, sex-cord stromal tumors, lymphomas) occurring more rarely. Germ cell tumors may also arise in extragonadal locations, such as the mediastinum and retroperitoneum.Remarkable progress has been made in the medical treatment of advanced testicular cancer with a substantial increase in cure rates from approximately 25% in the mid-1970s to nearly 80% today. 2 This cure rate is the highest of any solid tumor and improved survival is primarily due to effective chemotherapy. 3 It is important for all physicians to be familiar with this malignancy, because patients may initially present to a variety of practitioners, and delays in therapy are associated with more extensive disease resulting in more intensive treatment and lower cure rates. 4 In addition, the immediate and longterm toxic effects of treatment often require management from physicians of various disciplines. This article reviews the current evidence-based treatments for advanced testicular GCT, and the acute and chronic toxic effects that may result. The management of early stage (I-IIA) testicular cancers has been reviewed elsewhere. [5][6][7] BACKGROUND GCT Histology and GeneticsGerm cell tumors are malignancies of primordial germ cells, the cells destined to become spermatozoa. With neoplastic transformation, these cells take on a variety of histologies, reflect-See also Patient Page. CME available online at www.jamaarchivescme.com and questions on p 706.

show abstract

Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison.

Cited by 260 publications

References 30 publications

Improving stem cell mobilization strategies: future directions

Improving stem cell mobilization strategies: future directions

Mobilization of peripheral blood progenitor cells by disease-specific chemotherapy in patients with soft tissue sarcoma

Medical Treatment of Advanced Testicular Cancer

Contact Info

Product

Resources

About